ELI LILLY & Co (LLY)
Health Care · Pharmaceuticals · US stock · S&P 500 component
$1,257.03
▲ +5.42 (0.43%)
Fair valueOvervalued
$865 −31.2% to fair value
$433fair band $519–$1,211$1,298
Day's range
$1,251.25 – $1,274.56
52-week range
$778.94 – $1,292.65
About ELI LILLY & Co
Eli Lilly is a pharmaceutical company that discovers, develops and sells medicines. Its portfolio covers diabetes and obesity, cancer, immunology and neuroscience, and it markets products in many countries through its own sales organization and distribution partners. Revenue comes from prescription drug sales, which depend on patent protection, regulatory approvals and insurance reimbursement. The company spends heavily on research, and results reflect the success of its development pipeline.
Revenue has grown 31.7% a year over three years, leaving the last twelve months at $79.7 billion. Operating margin is 42.7%. Return on invested capital comes to 34%. On leverage, net debt to EBITDA is 1.3 times. A dividend is paid, with a yield of 0.5%. This gives an X-Ray Score of 64 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $778.94 – $1,292.65Volume 2,412,800Daily, split-adjusted
Vitals
Market cap$1.12T
52-week range$778.94 – $1,292.65
Volume (last day)2,412,800
P/E (TTM)42.2
EBIT / EV yield2.9%
Free-cash-flow yield–
Dividend yield0.5%
Revenue (TTM)$79.7B
Net income (TTM)$26.7B
Operating margin42.7%
Return on capital33.9%
Debt incl. leases$54.9B
Cash & securities$9.0B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$865model spread $587 – $877
Overvalued
−31.2% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Multiples use through-the-cycle earnings (0.65x of the last twelve months)
Peak-cycle earnings: the current operating margin is more than 1.5x its 7-year average, so the fair value range is widened
Price $1,257
Undervalued < $519Fair $519 – $1,211Overvalued > $1,211
10-year DCF (market-scaled)
$1,421
Peer multiples
$543
Earnings power floor (not blended)
$171
Fundamentals-adjusted multiple
$631
Growth the price implies
23.6%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
30/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield2.9%
Fair value vs price0.7×
Growth
Strong
90/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)31.7%
EPS growth (3y)49.3%
Growth consistency100%
Profitability
Fair
62/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital33.9%
Operating margin42.7%
Gross profitability46.7%
Financial health
Fair
69/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA1.3×
Interest coverNo interest cost
Dividends
Fair
63/100
Dividend is typical for its sector.
See the numbers →
Dividend yield0.5%
Dividend growth15.0%
Quarterly results: last 6 quarters
+45.2%
Mar '25
+37.6%
Jun '25
+53.9%
Sep '25
+42.6%
Dec '25
+55.5%
Mar '26
+47.7%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $23.0B, diluted EPS $7.94.
Compare with peers
ZTS Zoetis Inc.68 BMY Bristol Myers Squibb C...59 JNJ Johnson & Johnson50 MRK Merck & Co., Inc.32Other Pharmaceuticals companies by X-Ray Score.
Fundamentals checklist
● 9 Good · ● 2 Average · ● 3 BadCash quality
Earnings backed by cashBad
Risk models
Altman Z''Average
Piotroski F-ScoreGood
Growth
EPS growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioAverage
Net debt / EBITDAGood
Interest coverGood
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 59/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Operating income | $6.5B | $7.1B | $7.0B | $13.5B | $26.6B |
| Net income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| Operating cash flow | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B |
| Operating margin | 22.9% | 25.0% | 20.6% | 29.9% | 40.9% |
| Free cash flow | – | – | – | – | – |
| Diluted EPS | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 1,190.5 | Bullish |
| EMA 10 | 1,202.2 | Bullish |
| SMA 20 | 1,178.8 | Bullish |
| EMA 20 | 1,185.8 | Bullish |
| SMA 50 | 1,180.2 | Bullish |
| EMA 50 | 1,172.8 | Bullish |
| SMA 100 | 1,167.0 | Bullish |
| EMA 100 | 1,145.1 | Bullish |
| SMA 200 | 1,077.7 | Bullish |
| EMA 200 | 1,083.9 | Bullish |
Oscillators (daily)
| RSI (14) | 68.58 | Neutral |
| MACD (12, 26) | 15.51 | Bullish |
| Momentum (12) | 8.64 | Bullish |
| Stochastic %K (14) | 86.97 | Bearish |
| Williams %R (14) | -13.03 | Bearish |
| CCI (20) | 277.5 | Bearish |
Pivot points (classic, last session)
S3 1,224.0 | S2 1,237.6 | S1 1,247.3 | Pivot 1,260.9 | R1 1,270.6 | R2 1,284.3 | R3 1,294.0 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
6.69 USD
Yield on today's price
0.53%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 14 Aug 2026 | 1.7300 |
| 15 May 2026 | 1.7300 |
| 13 Feb 2026 | 1.7300 |
| 14 Nov 2025 | 1.5000 |
| 15 Aug 2025 | 1.5000 |
| 16 May 2025 | 1.5000 |
| 14 Feb 2025 | 1.5000 |
| 15 Nov 2024 | 1.3000 |
| 15 Aug 2024 | 1.3000 |
| 15 May 2024 | 1.3000 |
| 14 Feb 2024 | 1.3000 |
| 14 Nov 2023 | 1.1300 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
LLY SEC filings
5 Aug 2026
10-QSEC EDGAR
Quarterly report
5 Aug 2026
8-KSEC EDGAR
Results of operations
20 May 2026
8-KSEC EDGAR
Other events
7 May 2026
8-KSEC EDGAR
Shareholder vote results
30 Apr 2026
10-QSEC EDGAR
Quarterly report
30 Apr 2026
8-KSEC EDGAR
Results of operations
20 Mar 2026
DEF 14ASEC EDGAR
Proxy statement
12 Feb 2026
10-KSEC EDGAR
Annual report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.